HCWB Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (26 Apr 2024 @ 16:00):

HCW Biologics Inc., a preclinical stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases...

Stats
Today's Volume	2 442.00
Average Volume	15 695.00
Market Cap	52.95M
EPS	$-0.300 ( 2024-04-01 )
Next earnings date	( $0 ) 2024-05-14
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-2.00
ATR14	$0 (0.00%)

Insider Trading

Date	Person	Action	Amount	type
2024-02-20	Wong Hing C	Buy	739 288	Common Stock
2024-02-20	Greene Rick S.	Buy	35 714	Common Stock
2024-02-20	Giles Lisa M.	Buy	35 715	Common Stock
2024-02-20	Garrett Scott T	Buy	142 858	Common Stock
2024-02-20	Flowers Lee	Buy	71 429	Common Stock

INSIDER POWER
92.26
Last 100 transactions
Buy: 3 866 595 \| Sell: 3 743 515

HCW Biologics Inc. Correlation

10 Most Positive Correlations
CEG	0.899
CSSEP	0.897
CYRN	0.896
BIMI	0.892
FCBC	0.891
IRBT	0.889
DRUG	0.888
JAGX	0.888
CZNC	0.887
CSSE	0.878

10 Most Negative Correlations
BCOR	-0.917
AMTBB	-0.905
TZPS	-0.903
GLLI	-0.899
ARYD	-0.895
LCYAU	-0.894
MCAA	-0.893
EBACU	-0.892
SVFA	-0.89
TMKR	-0.888

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

HCW Biologics Inc. Financials

Annual	2023
Revenue:	$2.84M
Gross Profit:	$-574 824 (-20.23 %)
EPS:	$-0.700

FY	2023
Revenue:	$2.84M
Gross Profit:	$-574 824 (-20.23 %)
EPS:	$-0.700

FY	2022
Revenue:	$6.72M
Gross Profit:	$2.59M (38.48 %)
EPS:	$-0.410

FY	2021
Revenue:	$0.00
Gross Profit:	$0.00 (0.00 %)
EPS:	$-0.527

Financial Reports:

No articles found.

HCW Biologics Inc.

HCW Biologics Inc., a preclinical stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases. The company's lead products include HCW9218, which is an injectable immunotherapeutic for patients with pancreatic, ovarian, breast, prostate, and colorectal cancers, as well as pulmonary fibrosis; and HCW9302 for auto-immune diseases, such as alopecia areata and metabolic diseases. It also develops HCW9201, a cell-based therapy that is in Phase II clinical trials for the treatment of patients with relapsed/refractory acute myeloid leukemia; and HCW9206 for the treatment of acute myeloid leukemia. The company was incorporated in 2018 and is headquartered in Miramar, Florida.